がん医療におけるゲノミクスの世界市場分析:製品別(機器、消耗品、サービス)、用途別(診断、個別化医療、薬の発見・開発、研究)、技術別(ゲノム配列決定、PCR、マイクロアレイ、核酸抽出および精製)、エンドユーザー別(病院、研究機関、学術機関)、セグメント予測...市場調査レポートについてご紹介

【英文タイトル】Genomics In Cancer Care Market Analysis By Product (Instruments, Consumables, Services), By Application (Diagnostics, Personalized Medicine, Drug Discovery & Development, Research), By Technology (Genome Sequencing, PCR, Microarray, Nucleic Acid Extraction and Purification), By End-use (Hospitals, Research Institutes, Academic Institutes) And Segment Forecasts To 2022

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

Table of Content

Chapter 1. Methodology and Scope
1.1. Research methodology
1.2. Research scope & assumptions
1.3. List of data sources
Chapter 2. Executive Summary
2.1. Genomics in cancer care- Industry Snapshot And Key Buying Criteria, 2012-2022
Chapter 3. Genomics In Cancer Care Industry Outlook
3.1. Genomics in cancer care market segmentation
3.2. Genomics in cancer care market size and growth prospects
3.3. Genomics in cancer care market dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Key opportunities prioritized
3.5. Industry Analysis – Porter’s
3.6. Genomics in cancer care market PESTEL analysis, 2014
Chapter 4. Genomics In Cancer Care Product Outlook
4.1. Genomics in cancer care market share by product, 2014 & 2022
4.2. Instruments
4.2.1. Instruments market, 2012-2020 (USD Million)
4.3. Consumables & reagents
4.3.1. Consumables & reagents market, 2012 – 2020 (USD Million)
4.4. Services
4.4.1. Services market estimates and forecasts, 2012 f 2022 (USD Million)
Chapter 5. Genomics In Cancer Care Application Outlook
5.1. Genomics in cancer care revenue share by application, 2013 & 2020
5.2. Diagnostics
5.2.1. Market estimates and forecasts, 2012 – 2020 (USD Million)
5.3. Personalized medicine
5.3.1. Market estimates and forecasts, 2012 – 2020 (USD Million)
5.4. Drug discovery & development
5.4.1.Market estimates and forecasts, 2012 – 2020 (USD Million)
5.5. Research
5.5.1. Market estimates and forecasts, 2012 – 2020 (USD Million))
Chapter 6. Genomics In Cancer Care Technology Outlook
6.1. Genomics in cancer care revenue share by technology, 2013& 2020
6.2. Genome sequencing
6.2.1. Genome sequencing market estimates and forecasts, 2012 – 2020 (USD Million)
6.3. Polymerase chain reaction (PCR)
6.3.1. PCR market estimates and forecasts, 2012 – 2020 (USD Million)
6.4. Microarray
6.4.1. Microarray market estimates and forecasts, 2012 – 2020 (USD Million)
6.5. Nucleic acid extraction and purification
6.5.1. Nucleic acid extraction and purification market estimates and forecasts, 2012 – 2020 (USD Million)
6.6. Other (Flow cytometry, Bioinformatics)
6.6.1. Other market estimates and forecasts, 2012 – 2020 (USD Million)
Chapter 7. Genomics In Cancer Care End-use Outlook
7.1. Genomics in cancer care revenue share by end-use, 2013& 2020
7.2. Hospitals
7.2.1. Hospitals market estimates and forecasts, 2012 – 2020 (USD Million)
7.3. Research institutes
7.3.1. Research institutes market estimates and forecasts, 2012 – 2020 (USD Million)
7.4. Academic institutes
7.4.1. Academic institutes market estimates and forecasts, 2012 – 2020 (USD Million)
7.5. Others (diagnostic labs, commercial organizations & physician office)
7.5.1. Other market estimates and forecasts, 2012 – 2020 (USD Million)
Chapter 8. Genomics In Cancer Care Regional Outlook
8.1. Genomics in cancer care market share by region, 2014 & 2022
8.2. North America
8.2.1. North America Market Estimates and Forecasts, by Application, 2012 – 2022 (USD Million)
8.2.1.1. U.S. Market Estimates and Forecasts
8.2.1.2. Canada Market Estimates and Forecasts
8.3. Europe
8.3.1. Europe Market Estimates and Forecasts, by Application, 2012 – 2022 (USD Million)
8.3.1.1. Germany Market Estimates and Forecasts
8.3.1.2. UK Market Estimates and Forecasts
8.4. Asia Pacific
8.4.1. Asia Pacific Market Estimates and Forecasts, by Division, 2012 – 2022 (USD Million)
8.4.1.1. Japan Market Estimates and Forecasts
8.4.1.2. China Market Estimates and Forecasts
8.4.1.3. India Market Estimates and Forecasts
8.5. Latin America
8.5.1. Latin America Market Estimates and Forecasts, by Division, 2012 – 2022 (USD Million)
8.5.1.1. Brazil Market Estimates and Forecasts
8.5.1.2. Mexico Market Estimates and Forecasts
8.6. MEA
8.6.1. MEA Market Estimates and Forecasts, by Division, 2012 – 2022 (USD Million)
8.6.1.1. South Africa Estimates and Forecasts
Chapter 9. Competitive Landscape
9.1. Illumina Inc
9.1.1. Company Overview
9.1.2. Financial Performance
9.1.3. Product Benchmarking
9.1.4. Strategic Initiatives
9.2. Agilent Technologies
9.2.1. Company Overview
9.2.2. Financial Performance
9.2.3. Product Benchmarking
9.2.4. Strategic Initiatives
9.3. Roche Diagnostics
9.3.1. Company Overview
9.3.2. Financial Performance
9.3.3. Product Benchmarking
9.3.4. Strategic Initiatives
9.4. Cancer Genetics Inc
9.4.1. Company Overview
9.4.2. Financial Performance
9.4.3. Product Benchmarking
9.4.4. Strategic Initiatives
9.5. Bio-Rad Laboratories
9.5.1. Company Overview
9.5.2. Financial Performance
9.5.3. Product Benchmarking
9.5.4. Strategic Initiatives
9.6. Sigma Aldrich
9.6.1. Company Overview
9.6.2. Financial Performance
9.6.3. Product Benchmarking
9.6.4. Strategic Initiatives
9.7. Qiagen
9.7.1. Company Overview
9.7.2. Financial Performance
9.7.3. Product Benchmarking
9.7.4. Strategic Initiatives
9.8. Perkin Elmer
9.8.1. Company Overview
9.8.2. Financial Performance
9.8.3. Product Benchmarking
9.8.4. Strategic Initiatives
9.9. Affymetrix
9.9.1. Company Overview
9.9.2. Financial Performance
9.9.3. Product Benchmarking
9.9.4. Strategic Initiatives
9.10. BGI
9.10.1. Company Overview
9.10.2. Financial Performance
9.10.3. Product Benchmarking
9.10.4. Strategic Initiatives
9.11. Life technologies
9.11.1. Company Overview
9.11.2. Financial Performance
9.11.3. Product Benchmarking
9.11.4. Strategic Initiatives
9.12. GE Healthcare
9.12.1. Company Overview
9.12.2. Financial Performance
9.12.3. Product Benchmarking
9.12.4. Strategic Initiatives
9.13. Pacific Biosciences
9.13.1. Company Overview
9.13.2. Financial Performance
9.13.3. Product Benchmarking
9.13.4. Strategic Initiatives
9.14. Quest Diagnostics
9.14.1. Company Overview
9.14.2. Financial Performance
9.14.3. Product Benchmarking
9.14.4. Strategic Initiatives
9.15. Myriad Genetics
9.15.1. Company Overview
9.15.2. Financial Performance
9.15.3. Product Benchmarking
9.15.4. Strategic Initiatives
9.16. Luminex
9.16.1. Company Overview
9.16.2. Financial Performance
9.16.3. Product Benchmarking
9.16.4. Strategic Initiatives
9.17. Abbott Molecular
9.17.1. Company Overview
9.17.2. Financial Performance
9.17.3. Product Benchmarking
9.17.4. Strategic Initiatives
9.18. Beckman Coulter, Inc
9.18.1. Company Overview
9.18.2. Financial Performance
9.18.3. Product Benchmarking
9.18.4. Strategic Initiatives
9.19. Oxford Gene Technology Ltd.
9.19.1. Company Overview
9.19.2. Financial Performance
9.19.3. Product Benchmarking
9.19.4. Strategic Initiatives


【レポート販売概要】

■ タイトル:がん医療におけるゲノミクスの世界市場分析:製品別(機器、消耗品、サービス)、用途別(診断、個別化医療、薬の発見・開発、研究)、技術別(ゲノム配列決定、PCR、マイクロアレイ、核酸抽出および精製)、エンドユーザー別(病院、研究機関、学術機関)、セグメント予測
■ 英文:Genomics In Cancer Care Market Analysis By Product (Instruments, Consumables, Services), By Application (Diagnostics, Personalized Medicine, Drug Discovery & Development, Research), By Technology (Genome Sequencing, PCR, Microarray, Nucleic Acid Extraction and Purification), By End-use (Hospitals, Research Institutes, Academic Institutes) And Segment Forecasts To 2022
■ 発行日:2016年2月7日
■ 調査会社:Grand View Research
■ 商品コード:GVIEW707357
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。